Meeting Banner
Abstract #1999

Prediction of Treatment Response in Pancreatic Cancer Using EPR Oxygen Imaging

Shingo Matsumoto 1,2 , Keita Saito 1 , Jeeva P Munasinghe 3 , Nallathamby Devasahayam 1 , James B Mitchell 1 , Robert J Gillies 4 , and Murali C Krishna 1

1 Radiation Biology Branch, National Cancer Institute, NIH, Bethesda, MD, United States, 2 Hokkaido University, Sapporo, Hokkaido, Japan, 3 Mouse Imaging Facility, NINDS, NIH, Bethesda, MD, United States, 4 Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

Pancreatic cancer is a malignant neoplasm with an extremely poor prognosis. The TH-302 is a kind of drugs known as hypoxia-activated prodrug (HAP), which activated under hypoxia (low concentration of oxygen) and exhibits anti-tumor effect. A question derived is how clinicians select patients who receive most benefit from treatment with this hypoxia targeting new drug. Electron paramagnetic resonance imaging (EPRI) can non-invasively provide 3D absolute oxygen images. Here, we investigated if the EPR oxygen imaging can predict treatment benefit of oxygen dependent or independent therapies in three different pancreatic cancer xenografts.

This abstract and the presentation materials are available to members only; a login is required.

Join Here